EE04721B1 - Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine - Google Patents

Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine

Info

Publication number
EE04721B1
EE04721B1 EEP200100083A EEP200100083A EE04721B1 EE 04721 B1 EE04721 B1 EE 04721B1 EE P200100083 A EEP200100083 A EE P200100083A EE P200100083 A EEP200100083 A EE P200100083A EE 04721 B1 EE04721 B1 EE 04721B1
Authority
EE
Estonia
Prior art keywords
processes
preparation
phenylxanthine
derivatives
phenylxanthine derivatives
Prior art date
Application number
EEP200100083A
Other languages
English (en)
Estonian (et)
Inventor
Mary Daluge Susan
Holder Jurgensen Cynthia
Tolar Martin Michael
Howard Osterhout Martin
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200100083A publication Critical patent/EE200100083A/xx
Publication of EE04721B1 publication Critical patent/EE04721B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100083A 1998-08-13 1999-08-11 Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine EE04721B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds
PCT/EP1999/005814 WO2000009507A1 (en) 1998-08-13 1999-08-11 Phenyl yanthine derivatives

Publications (2)

Publication Number Publication Date
EE200100083A EE200100083A (et) 2002-06-17
EE04721B1 true EE04721B1 (et) 2006-10-16

Family

ID=10837179

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100083A EE04721B1 (et) 1998-08-13 1999-08-11 Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine

Country Status (36)

Country Link
US (3) US6608069B1 (enExample)
EP (1) EP1104422B1 (enExample)
JP (3) JP3631961B2 (enExample)
KR (1) KR20010085369A (enExample)
CN (2) CN1149215C (enExample)
AP (1) AP1408A (enExample)
AR (1) AR020154A1 (enExample)
AT (1) ATE259810T1 (enExample)
AU (1) AU775819B2 (enExample)
BR (1) BR9913020A (enExample)
CA (1) CA2340350A1 (enExample)
CO (1) CO5130007A1 (enExample)
DE (1) DE69914921T2 (enExample)
DK (1) DK1104422T3 (enExample)
EA (1) EA004139B1 (enExample)
EE (1) EE04721B1 (enExample)
ES (1) ES2215399T3 (enExample)
GB (1) GB9817623D0 (enExample)
HU (1) HUP0103637A3 (enExample)
ID (1) ID28723A (enExample)
IL (1) IL141318A0 (enExample)
IS (1) IS5843A (enExample)
MA (1) MA26673A1 (enExample)
MY (1) MY133393A (enExample)
NO (1) NO20010715L (enExample)
NZ (1) NZ509778A (enExample)
PE (1) PE20000952A1 (enExample)
PL (1) PL346055A1 (enExample)
PT (1) PT1104422E (enExample)
SI (1) SI1104422T1 (enExample)
SK (1) SK2222001A3 (enExample)
TR (1) TR200100448T2 (enExample)
TW (1) TWI224598B (enExample)
WO (1) WO2000009507A1 (enExample)
YU (1) YU11601A (enExample)
ZA (1) ZA200101186B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
WO2002067942A2 (en) * 2001-02-28 2002-09-06 Smithkline Beecham Corporation Methods of treating irritable bowel syndrome and functional dyspepsia
EP1418882A1 (en) 2001-08-24 2004-05-19 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
AU2002359365B2 (en) 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
WO2004009091A1 (en) 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010039289A2 (en) 2008-05-14 2010-04-08 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
AU2014262638A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994128B1 (en) * 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
AU2014262636A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
IL320958A (en) 2022-12-20 2025-07-01 Invios Gmbh 3,7-DIHYDRO-1 H-PURINE-2,6-DIONES TRANSFORMERS AND THEIR USES
EP4389749A1 (en) * 2022-12-20 2024-06-26 invIOs GmbH Substituted 3,7-dihydro-1h-purine-2,6-diones and use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (enExample) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5840302A (en) * 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
SI0812844T1 (en) 1996-06-07 2003-02-28 Hoechst Aktiengesellschaft Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU2640999A (en) 1998-02-26 1999-09-15 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2003523958A (ja) 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
EP1104422B1 (en) 2004-02-18
JP2004137251A (ja) 2004-05-13
US6770267B2 (en) 2004-08-03
MY133393A (en) 2007-11-30
YU11601A (sh) 2004-03-12
ID28723A (id) 2001-06-28
CA2340350A1 (en) 2000-02-24
PL346055A1 (en) 2002-01-14
PE20000952A1 (es) 2000-09-29
CN1251676C (zh) 2006-04-19
CO5130007A1 (es) 2002-02-27
DE69914921D1 (en) 2004-03-25
US6608069B1 (en) 2003-08-19
TR200100448T2 (tr) 2001-09-21
CN1323309A (zh) 2001-11-21
JP3631961B2 (ja) 2005-03-23
ES2215399T3 (es) 2004-10-01
KR20010085369A (ko) 2001-09-07
ZA200101186B (en) 2002-02-12
US20040034020A1 (en) 2004-02-19
AR020154A1 (es) 2002-04-10
TWI224598B (en) 2004-12-01
SK2222001A3 (en) 2001-12-03
AU775819B2 (en) 2004-08-19
US20030032804A1 (en) 2003-02-13
ATE259810T1 (de) 2004-03-15
EA004139B1 (ru) 2004-02-26
BR9913020A (pt) 2001-05-08
CN1515571A (zh) 2004-07-28
MA26673A1 (fr) 2004-12-20
SI1104422T1 (en) 2004-06-30
DE69914921T2 (de) 2004-12-23
WO2000009507A1 (en) 2000-02-24
AP2001002071A0 (en) 2001-03-31
GB9817623D0 (en) 1998-10-07
EP1104422A1 (en) 2001-06-06
AU5732399A (en) 2000-03-06
EE200100083A (et) 2002-06-17
HUP0103637A2 (en) 2002-06-29
IS5843A (is) 2001-02-09
CN1149215C (zh) 2004-05-12
DK1104422T3 (da) 2004-06-14
NO20010715D0 (no) 2001-02-12
NZ509778A (en) 2003-08-29
NO20010715L (no) 2001-04-02
AP1408A (en) 2005-05-06
IL141318A0 (en) 2002-03-10
JP2002522542A (ja) 2002-07-23
HK1035195A1 (en) 2001-11-16
JP2004115534A (ja) 2004-04-15
HUP0103637A3 (en) 2002-10-28
EA200100127A1 (ru) 2001-10-22
PT1104422E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
FI955235L (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
EE04849B1 (et) Asendatud fenüülderivaadid, nende valmistamine jakasutamine
EE200200175A (et) Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
FI955913A0 (fi) Uudet erytromysiinijohdannaiset, menetelmät niiden valmistamiseksi ja niiden käyttö lääkkeinä
EE03231B1 (et) Tetratsüklilised derivaadid, nende valmistamismeetod ja kasutamine
EE03568B1 (et) Bensimidasooli derivaadid, nende valmistamismeetod ja kasutamine
CY2013003I2 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20011216L (no) Azetidinderivater, deres fremstilling og medikamenter inneholdende forbindelsene
IS2076B (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
FI951468A7 (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
EE04236B1 (et) Bensimidasoolid, nende valmistamine ja kasutamineravimitena
EE200300245A (et) Bensotiofeeni derivaadid, nende valmistamise meetod ja kasutamine
ATE259810T1 (de) Phenyl-xanthinderivate
EE04497B1 (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
EE200100347A (et) 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
FI970997L (fi) Bentsosykloalkeeniyhdisteet, niiden valmistus ja käyttö

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20070811